^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TQB2825

    i
    Other names: TQB2825
    Associations

    News

    Trials
    Company:
    Sino Biopharm
    Drug class:
    CD20 inhibitor, CD3 agonist
    Related drugs:
    Associations

    News

    Trials
    over2years
    Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors (clinicaltrials.gov)
    P1, N=180, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
    New P1 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    TQB2825